Encorafenib

468 interactions 398 cited references
Also sold as: Braftovi Braftovi®
About Encorafenib

Encorafenib is used along with binimetinib (Mektovi) to treat certain types of melanoma (a type of skin cancer) that has spread to other parts of the body or cannot be removed by surgery. It is also used with cetuximab (Erbitux) to treat a certain type of colon cancer in adults that has spread to other parts of the bod… Read the full Encorafenib drug information page →

Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Atazanavir Posaconazole Ranolazine Piperaquine Doravirine Pimozide
36 Contraindicated 392 Major 40 Moderate
All (468) Contraindicated (36) Major (392) Moderate (40)

Major

Encorafenib Lurbinectedin Zepzelca Reduced lurbinectedin exposure and reduced efficacy of lurbinectedin Details Encorafenib Macimorelin Increased risk of QT interval prolongation Details Encorafenib Maraviroc Selzentry Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Maribavir Livtencity Reduced maribavir exposure and reduced efficacy of maribavir Details Encorafenib Mavorixafor Xolremdi An increased risk of QT interval prolongation and torsade de pointes Details Encorafenib Medroxyprogesterone Amen® Reduced hormonal contraceptives exposure and reduced efficacy of hormonal contraceptives Details Encorafenib Mefloquine Lariam® Increased risk of QT interval prolongation Details Encorafenib Mestranol Reduced hormonal contraceptives exposure and reduced efficacy of hormonal contraceptives Details Encorafenib Methadone Diskets Increased risk of QT interval prolongation Details Encorafenib Methotrimeprazine Increased risk of QT interval prolongation Details Encorafenib Methylergonovine Methergine Reduced methylergonovine exposure and reduced efficacy of methylergonovine Details Encorafenib Metronidazole Flagyl Increased risk of QT interval prolongation Details Encorafenib Midazolam Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Midostaurin Rydapt Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Mifepristone Korlym Increased encorafenib exposure, reduced miFEPRIStone exposure and an increased risk of QT interval prolongation Details Encorafenib Milsaperidone An increased risk of QT interval prolongation Details Encorafenib Mirtazapine Mirataz Increased risk of QT interval prolongation and torsades de pointes Details Encorafenib Mitapivat Aqvesme Reduced mitapivat exposure and reduced efficacy of mitapivat Details Encorafenib Mitotane Lysodren Reduced encorafenib exposure and reduced efficacy of encorafenib Details Encorafenib Mizolastine Increased risk of QT interval prolongation Details Encorafenib Mobocertinib Exkivity Reduced mobocertinib exposure, reduced efficacy of mobocertinib and an increased risk of QT interval prolongation Details Encorafenib Modafinil Provigil Reduced encorafenib exposure and reduced efficacy of encorafenib Details Encorafenib Moricizine Increased risk of QT interval prolongation Details Encorafenib Moxifloxacin Avelox Increased risk of QT interval prolongation Details Encorafenib Nafcillin Reduced encorafenib exposure and reduced efficacy of encorafenib Details Encorafenib Naloxegol Movantik Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Nefazodone Increased encorafenib exposure and an increased risk of encorafenib-related adverse events Details Encorafenib Nelfinavir Viracept Increased encorafenib exposure, an increased risk of encorafenib-related adverse reactions and an increased risk of QT interval pr... Details Encorafenib Nerandomilast Reduced nerandomilast exposure and reduced efficacy of nerandomilast Details Encorafenib Netupitant Increased encorafenib exposure and an increased risk of encorafenib-related adverse events Details Encorafenib Nilotinib Increased encorafenib exposure, an increased risk of encorafenib-related adverse reactions and an increased risk of QT interval pr... Details Encorafenib Nirmatrelvir Increased encorafenib exposure, increased risk of QT interval prolongation, reduced nirmatrelvir exposure and reduced efficacy of... Details Encorafenib Nirogacestat Ogsiveo Increased encorafenib exposure, an increased risk of encorafenib-related adverse reactions, reduced sensitive CYP3A4 substrate exp... Details Encorafenib Nisoldipine Sular Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Nomegestrol Reduced hormonal contraceptives exposure and reduced efficacy of hormonal contraceptives Details Encorafenib Norelgestromin Reduced hormonal contraceptives exposure and reduced efficacy of hormonal contraceptives Details Encorafenib Norethindrone Aygestin Reduced hormonal contraceptives exposure and reduced efficacy of hormonal contraceptives Details Encorafenib Norfloxacin Increased risk of QT interval prolongation Details Encorafenib Norgestimate Reduced hormonal contraceptives exposure and reduced efficacy of hormonal contraceptives Details Encorafenib Norgestrel Reduced hormonal contraceptives exposure and reduced efficacy of hormonal contraceptives Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.